The DOI matches its Crossref record; 152 of the 152 references it cites were found in a registry or an index.
Apolipoprotein E in Alzheimer's Disease: An Update
Open accessAbstract
The vast majority of Alzheimer's disease (AD) cases are late onset (LOAD), which is genetically complex with heritability estimates up to 80%. Apolipoprotein E (APOE) has been irrefutably recognized as the major genetic risk factor, with semidominant inheritance, for LOAD. Although the mechanisms that underlie the pathogenic nature of APOE in AD are still not completely understood, emerging data suggest that APOE contributes to AD pathogenesis through both amyloid-β (Aβ)-dependent and Aβ-independent pathways. Given the central role for APOE in the modulation of AD pathogenesis, many therapeutic strategies have emerged, including converting APOE conformation, regulating APOE expression, mimicking APOE peptides, blocking the APOE/Aβ interaction, modulating APOE lipidation state, and gene therapy. Accumulating evidence also suggests the utility of APOE genotyping in AD diagnosis, risk assessment, prevention, and treatment response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ApoE isoforms encoded by various APOE alleles differentially influence the rate of soluble Aβ clearance from the brain interstitial space and formation of Aβ parenchymal plaques and VAβ [32, 33].”
From APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice (2017) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The ɛ4 allele has detrimental effects on production, deposition, and clearance of amyloid-β, in phosphorylation of tau, in neurotoxicity, mitochondrial dysfunction, and in blood–brain barrier permeability.57,59,60”
From Plasma levels of apolipoprotein E, APOE genotype, and all-cause and cause-specific mortality in 105 949 individuals from a white general population cohort (2019) · cites this paper as [57]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Plausible mechanisms underlying the association between low apoE levels and dementia-associated mortality are not explained by peripheral lipid metabolism, but likely by the role of apoE in β-amyloid handling and in neurodegenerative processes.57,58”
From Plasma levels of apolipoprotein E, APOE genotype, and all-cause and cause-specific mortality in 105 949 individuals from a white general population cohort (2019) · cites this paper as [57]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“APOE genotype critically affects the burden of Aβ pathology in sporadic AD.”
From APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice (2017) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Integrative genomics identifies APOE ε4 effectors in Alzheimer's disease
Rhinn, H., Fujita, R., Qiang, L., Cheng, R., Lee, J. H., & Abeliovich, A. (2013) · Nature · doi:10.1038/nature12415 · Cited by 151
RetractedMcKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Meta-Analysis of 74,046 Individuals Identifies 11 New Susceptibility Loci for Alzheimer’s Disease
(EADI), E. A. D. I., Lambert, J.-C., (GERAD), G. A. E. R. I. A. D., Alzheimer's Disease Genetic Consortium (ADGC), (CHARGE), C. F. H. A. A. R. I. G. E., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2802 · Cited by 4,336
Self-citationApolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459
2013 Alzheimer's disease facts and figures
Thies, W. H., & Bleiler, L. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.02.003 · Cited by 3,372
TREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020
Self-citationNeurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders
Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969
Variant of TREM2 Associated with the Risk of Alzheimer's Disease
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558
Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078
Research works printed but not linked: 2
- Cacabelos R, 2012, Int. J. Alzheimer's Dis., 2012, 518901
- Wahrle SE, 2008, J. Clin. Investig., 118, 671
Cited by
Sorted by citations
Preclinical Alzheimer’s Disease: Definition, Natural History, and Diagnostic Criteria
Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., Bakardjian, H., Benali, H., Bertram, L., Blennow, K., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.002 · Cited by 1,925
A systemic view of Alzheimer disease — insights from amyloid-β metabolism beyond the brain
Wang, J., Gu, B. J., Masters, C. L., & Wang, Y.-J. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.111 · Cited by 808
A Quarter Century of APOE and Alzheimer’s Disease: Progress to Date and the Path Forward
Belloy, M. E., Napolioni, V., & Greicius, M. D. (2019) · Neuron · doi:10.1016/j.neuron.2019.01.056 · Cited by 570
Liu, L., MacKenzie, K. R., Putluri, N., Maletić-Savatić, M., & Bellen, H. J. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.08.024 · Cited by 556
Microbes and Alzheimer’s Disease
Itzhaki, R. F., Lathe, R., Balin, B. J., Ball, M. J., Bearer, E. L., Braak, H., Bullido, M. J., Carter, C., Clerici, M., Cosby, S. L., et al. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160152 · Cited by 532
Donohue, M. C., Sperling, R. A., Petersen, R., Sun, C.-K., Weiner, M. W., Aisen, P. S., & Initiative, F. T. A. D. N. (2017) · JAMA · doi:10.1001/jama.2017.6669 · Cited by 452
Zhao, J., Fu, Y., Yamazaki, Y., Ren, Y., Davis, M. D., Liu, C.-C., Lu, W., Wang, X., Chen, K., Cherukuri, Y., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19264-0 · Cited by 374
APOE and Alzheimer’s Disease: From Lipid Transport to Physiopathology and Therapeutics
Husain, M. A., Laurent, B., & Plourde, M. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.630502 · Cited by 353
Lysosomal cathepsins and their regulation in aging and neurodegeneration
Stoka, V., Turk, V., & Turk, B. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.04.010 · Cited by 334
16S rRNA Next Generation Sequencing Analysis Shows Bacteria in Alzheimer’s Post-Mortem Brain
Emery, D. C., Shoemark, D. K., Batstone, T. E., Waterfall, C. M., Coghill, J. A., Cerajewska, T. L., Davies, M., West, N. X., & Allen, S. J. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00195 · Cited by 317
Lewczuk, P., Riederer, P. F., O’Bryant, S. E., Verbeek, M. M., Dubois, B., Visser, P. J., Jellinger, K. A., Engelborghs, S., Ramírez, A., Parnetti, L., et al. (2017) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1375556 · Cited by 318
Tan, M., Yu, J., Tan, C., Wang, H.-F., Meng, X., Wang, C., Jiang, T., Zhu, X., & Tan, L. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-140837 · Cited by 253
Self-citationProteomic differences in amyloid plaques in rapidly progressive and sporadic Alzheimer’s disease
Drummond, E., Nayak, S., Faustin, A., Pires, G., Hickman, R. A., Askenazi, M., Cohen, M., Haldiman, T., Kim, C., Han, X., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1691-0 · Cited by 239
Retromer in Alzheimer disease, Parkinson disease and other neurological disorders
Small, S. A., & Petsko, G. A. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3896 · Cited by 227
Tau in neurodegenerative disease
Gao, Y.-L., Wang, N., Sun, F.-R., Cao, X.-P., Zhang, W., & Yu, J.-T. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.04.23 · Cited by 222
Self-citationOxidant/Antioxidant Imbalance in Alzheimer’s Disease: Therapeutic and Diagnostic Prospects
Wojsiat, J., Zoltowska, K. M., Laskowska-Kaszub, K., & Wojda, U. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/6435861 · Cited by 221
REST and neural gene network dysregulation in iPSC models of Alzheimer’s disease
Meyer, K., Feldman, H. M., Lu, T., Drake, D., Lim, E. T., Ling, K.-H., Bishop, N. A., Pan, Y., Seo, J., Lin, Y.-T., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.01.023 · Cited by 216
Solomon, A., Turunen, H., Ngandu, T., Peltonen, M., Levälahti, E., Helisalmi, S., Antikainen, R., Bäckman, L., Hänninen, T., Jula, A., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2017.4365 · Cited by 213
Amyloid clearance defect in ApoE4 astrocytes is reversed by epigenetic correction of endosomal pH
Prasad, H., & Rao, R. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1801612115 · Cited by 207
Aducanumab: Appropriate Use Recommendations Update
Cummings, J. L., Rabinovici, G. D., Atri, A., Aisen, P. S. S., Apostolova, L. G., Hendrix, S. B., Sabbagh, M. N., Selkoe, D. J., Weiner, M. W., & Salloway, S. (2022) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2022.34 · Cited by 204
Gene-based therapies for neurodegenerative diseases
Sun, J., & Roy, S. (2021) · Nature Neuroscience · doi:10.1038/s41593-020-00778-1 · Cited by 194
Concussion in chronic traumatic encephalopathy
Stein, T. D., Alvarez, V. E., & McKee, A. C. (2015) · Current Pain and Headache Reports · doi:10.1007/s11916-015-0522-z · Cited by 177
Astrocytes in Alzheimer's disease: pathological significance and molecular pathways
Preman, P., Alfonso-Triguero, M., Alberdi, E., Verkhratsky, A., & Arranz, A. M. (2021) · Cells · doi:10.3390/cells10030540 · Cited by 176
Tau Proteolysis in the Pathogenesis of Tauopathies: Neurotoxic Fragments and Novel Biomarkers
Quinn, J. P., Corbett, N. J., Kellett, K. A. B., & Hooper, N. M. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-170959 · Cited by 170
Qian, J., Wolters, F. J., Beiser, A., Haan, M., Ikram, M. A., Karlawish, J., Langbaum, J. B., Neuhaus, J. M., Reiman, E. M., Roberts, J. S., et al. (2017) · PLOS Medicine · doi:10.1371/journal.pmed.1002254 · Cited by 169
Peng, J., Pang, J., Huang, L., Enkhjargal, B., Zhang, T., Mo, J., Wu, P., Xu, W., Zuo, Y., Peng, J., et al. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101121 · Cited by 160
The Role of ADAM10 in Alzheimer’s Disease
Yuan, X., Sun, S., Tan, C., Yu, J., & Tan, L. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170061 · Cited by 160
Self-citationEmerging links between cerebrovascular and neurodegenerative diseases—a special role for pericytes
Lendahl, U., Nilsson, P., & Betsholtz, C. (2019) · EMBO Reports · doi:10.15252/embr.201948070 · Cited by 148
What is the Relationship of Traumatic Brain Injury to Dementia?
Mendez, M. F. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161002 · Cited by 141
Lundin, A., Delsing, L., Clausen, M., Ricchiuto, P., Sánchez, J., Sabirsh, A., Ding, M., Synnergren, J., Zetterberg, H., Brolén, G., et al. (2018) · Stem Cell Reports · doi:10.1016/j.stemcr.2018.01.021 · Cited by 128
Tan, J. Z. A., & Gleeson, P. A. (2019) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2018.11.013 · Cited by 137
Rasmussen, K. L. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.10.037 · Cited by 125
Microglial priming in Alzheimer’s disease
Li, J.-W., Zong, Y., Cao, X.-P., Tan, L., & Tan, L. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.04.22 · Cited by 122
Self-citationThe Role of PICALM in Alzheimer’s Disease
Xu, W., Tan, L., & Yu, J. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8878-3 · Cited by 124
Self-citationThe amyloid cascade and Alzheimer's disease therapeutics: theory versus observation
Castellani, R. J., Plascencia‐Villa, G., & Perry, G. L. (2019) · Laboratory Investigation · doi:10.1038/s41374-019-0231-z · Cited by 130
Alzheimer's Disease Mechanisms and Emerging Roads to Novel Therapeutics
Sala Frigerio, C., & De Strooper, B. (2016) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-070815-014015 · Cited by 116
Statins and the Brain: More than Lipid Lowering Agents?
Fracassi, A., Marangoni, M., Rosso, P., Pallottini, V., Fioramonti, M., Siteni, S., & Segatto, M. (2018) · Current Neuropharmacology · doi:10.2174/1570159x15666170703101816 · Cited by 116
Ma, J., Jiang, T., Tan, L., & Yu, J.-T. (2015) · Molecular Neurobiology · doi:10.1007/s12035-014-8811-9 · Cited by 113
Self-citationSynaptic Amyloid-β Oligomers Precede p-Tau and Differentiate High Pathology Control Cases
Bilousova, T., Miller, C. A., Poon, W. W., Vinters, H. V., Corrada, M., Kawas, C., Hayden, E. Y., Teplow, D. B., Glabe, C., Albay, R., et al. (2016) · The American Journal of Pathology · doi:10.1016/j.ajpath.2015.09.018 · Cited by 115
Mao, Y., Guo, Z., Zheng, T., Jiang, Y., Yan, Y., Yin, X., Chen, Y., & Zhang, B. (2016) · Aging Cell · doi:10.1111/acel.12498 · Cited by 113
An, J., Kim, K., Lim, H. J., Kim, H. Y., Shin, J. W., Park, I., Cho, I., Kim, H. Y., Kim, S., McLean, C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-44818-x · Cited by 116
Zhao, L., Gottesdiener, A. J., Parmar, M., Li, M., Kaminsky, S. M., Chiuchiolo, M. J., Sondhi, D., Sullivan, P. M., Holtzman, D. M., Crystal, R. G., et al. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.04.020 · Cited by 107
The Exceptional Vulnerability of Humans to Alzheimer’s Disease
Walker, L. C., & Jucker, M. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.04.001 · Cited by 108
Innate Immunity Fights Alzheimer's Disease
Guillot‐Sestier, M., Doty, K. R., & Town, T. (2015) · Trends in Neurosciences · doi:10.1016/j.tins.2015.08.008 · Cited by 101
Association of Brain Amyloid-β With Slow Gait in Elderly Individuals Without Dementia
Nadkarni, N. K., Perera, S., Snitz, B. E., Mathis, C. A., Price, J. C., Williamson, J. D., DeKosky, S. T., Klunk, W. E., & López, O. L. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.3474 · Cited by 94
Bello‐Chavolla, O. Y., Antonio‐Villa, N. E., Vargas‐Vázquez, A., Ávila‐Funes, J. A., & Aguilar-Salinas, C. A. (2019) · Current Diabetes Reviews · doi:10.2174/1573399815666190129155654 · Cited by 96
Alzheimer’s disease and type 2 diabetes mellitus: Pathophysiologic and pharmacotherapeutics links
Rojas, M., Chávez-Castillo, M., Bautista, J., Ortega, Á., Nava, M., Salazar, J. J., Díaz-Camargo, E. A., Medina, O., Rojas, J., & Bermúdez, V. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i6.745 · Cited by 98
Keeney, J. T.-R., Ibrahimi, S., & Zhao, L. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-150348 · Cited by 102
The Role of MAPT in Neurodegenerative Diseases: Genetics, Mechanisms and Therapy
Zhang, C., Xing, A., Tan, M., Tan, L., & Yu, J. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9415-8 · Cited by 98
Self-citationAbsolute 10-year risk of dementia by age, sex and APOE genotype: a population-based cohort study
Rasmussen, K. L., Tybjærg-Hansen, A., Nordestgaard, B. G., & Frikke-Schmidt, R. (2018) · Canadian Medical Association Journal · doi:10.1503/cmaj.180066 · Cited by 91
Poey, J. L., Burr, J. A., & Roberts, J. S. (2017) · The Gerontologist · doi:10.1093/geront/gnw154 · Cited by 99
Rasmussen, K. L., Tybjærg-Hansen, A., Nordestgaard, B. G., & Frikke-Schmidt, R. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz402 · Cited by 86
Kynurenine Pathway Metabolites as Biomarkers in Alzheimer’s Disease
Liang, Y., Xie, S., He, Y., Xu, M., Qiao, X., Zhu, Y. H., & Wu, W. (2022) · Disease Markers · doi:10.1155/2022/9484217 · Cited by 92
Axonal Transport Defects in Alzheimer’s Disease
Wang, Z., Tan, L., & Yu, J. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8810-x · Cited by 92
Self-citationAlzheimer's Disease Puzzle: Delving into Pathogenesis Hypotheses
(2024) · aging and disease · doi:10.14336/ad.2023.0608 · Cited by 183
Nanomaterials towards Biosensing of Alzheimer’s Disease Biomarkers
Carneiro, P., Morais, S., & Pereira, M. D. C. (2019) · Nanomaterials · doi:10.3390/nano9121663 · Cited by 85
Manzine, P. R., Ettcheto, M., Cano, A. C., Busquets, O., Marcello, E. E., Pelucchi, S., Luca, M. D., Endres, K., Olloquequi, J., Camins, A., et al. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.108661 · Cited by 84
Quantitative Analysis of the Brain Ubiquitylome in Alzheimer's Disease
Abreha, M. H., Dammer, E. B., Ping, L., Zhang, T., Duong, D. M., Gearing, M., Lah, J. J., Levey, A. I., & Seyfried, N. T. (2018) · PROTEOMICS · doi:10.1002/pmic.201800108 · Cited by 82
The Complex Role of Apolipoprotein E in Alzheimer’s Disease: an Overview and Update
Mahoney‐Sanchez, L., Belaidi, A. A., Bush, A. I., & Ayton, S. (2016) · Journal of Molecular Neuroscience · doi:10.1007/s12031-016-0839-z · Cited by 84
Hernández, D., Rooney, L. A., Daniszewski, M., Gulluyan, L. M., Liang, H. H., Cook, A. L., Hewitt, A. W., & Pébay, A. (2021) · Stem Cell Reviews and Reports · doi:10.1007/s12015-021-10147-5 · Cited by 79
Ullah, R., Park, T. J., Huang, X., & Kim, M. O. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101451 · Cited by 78
Chlamydia pneumoniae: An Etiologic Agent for Late-Onset Dementia
Balin, B. J., Hammond, C. J., Little, C. S., Hingley, S. T., Al-Atrache, Z., Appelt, D. M., Whittum-Hudson, J. A., & Hudson, A. P. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00302 · Cited by 77
Hampel, H. J., Schneider, L. S., Giacobini, E., Kivipelto, M., Sindi, S., Dubois, B., Broich, K., Nisticò, R., Aisen, P. S. S., & Lista, S. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.995637 · Cited by 82
PICALM Rescues Endocytic Defects Caused by the Alzheimer’s Disease Risk Factor APOE4
Narayan, P., Sienski, G., Bonner, J. M., Lin, Y.-T., Seo, J., Baru, V., Haque, A., Milo, B., Akay, L. A., Graziosi, A., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108224 · Cited by 75
He, Z.-X., Chen, X.-W., Zhou, Z.-W., & Zhou, S.-F. (2015) · Drug Metabolism Reviews · doi:10.3109/03602532.2015.1101131 · Cited by 76
Hubin, E., Verghese, P. B., van Nuland, N., & Broersen, K. (2019) · FEBS Letters · doi:10.1002/1873-3468.13428 · Cited by 73
Rygiel, K. (2016) · Indian Journal of Pharmacology · doi:10.4103/0253-7613.194867 · Cited by 76
(ADNI), F. T. A. D. N. I., Yan, Q., Nho, K., Del-Aguila, J. L., Wang, X., Risacher, S. L., Fan, K.-H., Snitz, B. E., Aizenstein, H. J., Mathis, C. A., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-018-0246-7 · Cited by 73
The Role of Cholesterol Metabolism in Alzheimer’s Disease
Sun, J.-H., Yu, J.-T., & Tan, L. (2015) · Molecular Neurobiology · doi:10.1007/s12035-014-8749-y · Cited by 70
Self-citationMendonça, C. F., Kuras, M., Nogueira, F. C. S., Plá, I., Hortobágyi, T., Csiba, L., Palkovits, M., Renner, É., Döme, P., Marko‐Varga, G., et al. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104509 · Cited by 69
Prion-like mechanisms in Alzheimer disease
Walker, L. C. (2018) · Handbook of clinical neurology · doi:10.1016/b978-0-444-63945-5.00016-7 · Cited by 67
Nanoparticle-mediated growth factor delivery systems: A new way to treat Alzheimer's disease
Lauzon, M.-A., Daviau, A., Marcos, B., & Faucheux, N. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.03.024 · Cited by 66
Tan, L., Wang, H.-F., Tan, M., Tan, C., Zhu, X., Miao, D., Yu, W.-J., Jiang, T., Tan, L., Yu, J., et al. (2016) · Scientific Reports · doi:10.1038/srep26027 · Cited by 66
Self-citationProteopathic Strains and the Heterogeneity of Neurodegenerative Diseases
Walker, L. C. (2016) · Annual Review of Genetics · doi:10.1146/annurev-genet-120215-034943 · Cited by 60
Herpes Viruses and Senile Dementia: First Population Evidence for a Causal Link
Itzhaki, R. F., & Lathe, R. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180266 · Cited by 63
Fišar, Z., Hansíková, H., Křížová, J., Jirák, R., Kitzlerová, E., Zvěřová, M., Hroudová, J., Wenchich, L., Zeman, J., & Raboch, J. (2019) · Mitochondrion · doi:10.1016/j.mito.2019.07.013 · Cited by 64
Lipid Biomarkers for Amyotrophic Lateral Sclerosis
de Aguilar, J. G. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00284 · Cited by 62
Zhang, T., Guo, J., Gu, J., Wang, Z., Wang, G., Li, H., & Wang, J. (2018) · Oncology Reports · doi:10.3892/or.2018.6840 · Cited by 62
Sleep and circadian rhythm disruption and stress intersect in Alzheimer's disease
Phan, T., & Malkani, R. G. (2018) · Neurobiology of Stress · doi:10.1016/j.ynstr.2018.10.001 · Cited by 66
Ulv Larsen, S. M., Landolt, H.-P., Berger, W., Nedergaard, M., Knudsen, G. M., & Holst, S. C. (2020) · PLOS Biology · doi:10.1371/journal.pbio.3000623 · Cited by 60
Kauppi, K., Fan, C. C., McEvoy, L. K., Holland, D., Tan, C. H., Chen, C.-H., Andreassen, O. A., Desikan, R. S., Dale, A. M., & Initiative, T. A. D. N. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00260 · Cited by 60
Increased amyloidogenic APP processing in APOE ɛ4-negative individuals with cerebral β-amyloidosis
Mattsson, N., Insel, P. S., Palmqvist, S., Stomrud, E., van Westen, D., Minthon, L., Zetterberg, H., Blennow, K., & Hansson, O. (2016) · Nature Communications · doi:10.1038/ncomms10918 · Cited by 60
Biosensors on the road to early diagnostic and surveillance of Alzheimer's disease
Carneiro, P., Morais, S., & Pereira, M. D. C. (2020) · Talanta · doi:10.1016/j.talanta.2019.120700 · Cited by 59
Alzheimer’s disease, apolipoprotein E and hormone replacement therapy
Depypere, H. T., Vierin, A., Weyers, S., & Sieben, A. (2016) · Maturitas · doi:10.1016/j.maturitas.2016.09.009 · Cited by 60
Apolipoprotein E deficiency accelerates atherosclerosis development in miniature pigs
Fang, B., Ren, X., Wang, Y., Li, Z., Zhao, L., Zhang, M., Chu, L., Zhang, Z., Chen, L., Li, X., et al. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.036632 · Cited by 55
Baker-Nigh, A. T., Mawuenyega, K. G., Bollinger, J. G., Ovod, V., Kasten, T., Franklin, E. E., Liao, F., Jiang, H., Holtzman, D., Cairns, N. J., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.721779 · Cited by 54
“Disease modifying nutricals” for multiple sclerosis
Schmitz, K., Barthelmes, J., Stolz, L., Beyer, S., Diehl, O., & Tegeder, I. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.015 · Cited by 55
Zheng, J., Sun, J., Ji, C.-M., Shen, L., Chen, Z.-J., Xie, P., Sun, Y.-Z., & Yu, R. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.03.002 · Cited by 54
Visual Features in Alzheimer’s Disease: From Basic Mechanisms to Clinical Overview
Cerquera-Jaramillo, M. A., Nava-Mesa, M. O., González-Reyes, R. E., Téllez-Conti, C., & de‐la‐Torre, A. (2018) · Neural Plasticity · doi:10.1155/2018/2941783 · Cited by 61
Bilousova, T. V., Melnik, M., Miyoshi, E., Gonzalez, B. L., Poon, W. W., Vinters, H. V., Miller, C. A., Corrada, M. M., Kawas, C. H., Hatami, A., et al. (2019) · American Journal Of Pathology · doi:10.1016/j.ajpath.2019.04.010 · Cited by 57
MS4A Cluster in Alzheimer’s Disease
Ma, J., Yu, J., & Tan, L. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8800-z · Cited by 54
Self-citationXu, H., Tan, L., Tan, M., Tan, M., Zheng, Z.-J., Zheng, Z.-J., Kong, L.-L., Wang, Z.-X., Jiang, T., Tan, L., et al. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-9698-4 · Cited by 51
Self-citationMeta-analysis of the association between variants in MAPT and neurodegenerative diseases
Zhang, C., Zhu, J., Wan, Y., Tan, L., Wang, H.-F., Yu, J., & Tan, L. (2017) · Oncotarget · doi:10.18632/oncotarget.16690 · Cited by 57
Self-citationPhysical Activity in Preventing Alzheimer’s Disease and Cognitive Decline: A Narrative Review
Brini, S., Sohrabi, H. R., Peiffer, J. J., Karrasch, M., Hämäläinen, H., Martins, R. N., & Fairchild, T. J. (2017) · Sports Medicine · doi:10.1007/s40279-017-0787-y · Cited by 62
Pascual-Caro, C., Berrocal, M., López-Guerrero, A. M., Alvarez, A. M., Pozo‐Guisado, E., Gutiérrez‐Merino, C., Mata, A. M., & Martı́n-Romero, F. J. (2018) · Journal of Molecular Medicine · doi:10.1007/s00109-018-1677-y · Cited by 56
Updated Meta-Analysis of BIN1, CR1, MS4A6A, CLU, and ABCA7 Variants in Alzheimer’s Disease
Almeida, J. F. F., dos Santos, L. R., Trancozo, M., & Paula, F. (2018) · Journal of Molecular Neuroscience · doi:10.1007/s12031-018-1045-y · Cited by 52
Impairment of Dendrodendritic Inhibition in the Olfactory Bulb of APP/PS1 Mice
Li, W., Li, S., Shen, L., Wang, J., Wu, X., Li, J., Tu, C., Ye, X., & Ling, S. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00002 · Cited by 51
Initiative, A. D. N., Liu, Y., Tan, L., Wang, H.-F., Liu, Y., Hao, X., Tan, C., Jiang, T., Liu, B., Zhang, D., et al. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9388-7 · Cited by 54
Self-citationSmall, S. A. (2014) · Neuron · doi:10.1016/j.neuron.2014.08.030 · Cited by 55
Management Perspective of Wilsons Disease: Early Diagnosis and Individualized Therapy
Yuan, X., Yang, R., & Wang, X. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200429233517 · Cited by 52
Metadata
- Authors
- Yu, J.-T., Tan, L., & Hardy, J.
- Affiliations
- Qingdao University (CN)
- UCL Queen Square Institute of Neurology (GB)
- Venue
- Annual Review of Neuroscience
- Publisher
- Annual Reviews
- Published
- 2014-07-08
- Volume
- 37
- Issue
- 1
- Pages
- 79-100
- ISSN
- 0147-006X (ISSN-L)
- 1545-4126
- OpenAlex
- W2097112082
- Cited by
- 394
- References
- 152
- Citations by year
- 2026: 7 · 2025: 15 · 2024: 27 · 2023: 20 · 2022: 26 · 2021: 32 · 2020: 39 · 2019: 46 · 2018: 47 · 2017: 46 · 2016: 46 · 2015: 27 · 2014: 14
- FWCI
- 5.19
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Annual Review of Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- National Natural Science Foundation of China (81000544, 81171209)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- apolipoprotein E, Alzheimer's disease, late-onset Alzheimer's disease, genetic risk factors, amyloid-beta, gene therapy, APOE genotyping, treatment options
- MeSH terms
- Alzheimer Disease, Apolipoproteins E, Brain, Genotype, Humans, Models, Biological, Signal Transduction, Amyloid beta-Peptides, tau Proteins, Genetic Predisposition to Disease, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
